GoKawiilNew review maps molecular drivers behind MASH and MASLD subtypes
A newly compiled research review synthesizes recent findings on metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, tracing the field from its 1980 origins as NASH to the 2023 multisociety nomenclature update. It highlights recent multiomic and genetic studies showing that MASLD is not one uniform disease but splits into at least two distinct subtypes—one driven mainly by liver-specific factors and another tied to broader cardiometabolic dysfunction. The review also draws on global epidemiological data covering adult, pediatric and adolescent populations to frame the disease's rising burden.
GoKawiil's interpretation of the reporting above, not reported fact.
Recognizing that fatty liver disease splits into genetically and mechanistically distinct subgroups could reshape how doctors screen, monitor and treat patients, since a one-size-fits-all approach may miss key risk factors for different populations. The rebranding from NAFLD/NASH to MASLD/MASH reflects a broader push to link liver disease directly to metabolic health, which could influence drug development and clinical trial design going forward. With rising rates among young people and its connection to liver cancer, refining classification could speed earlier intervention.
- MASLD/MASH terminology replaces older NAFLD/NASH nomenclature following a 2023 international consensus.
- Genetic and multiomic studies indicate at least two distinct MASLD subtypes: liver-centric and cardiometabolic-centric.
- The disease burden is rising among adolescents and young adults, prompting increased focus on pediatric MASLD research.
Source: nature.com — Gallage, 2026-09-02
Published there as: “Molecular mechanisms and pathogenesis of MASH”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.